Antibodies to heteromeric glycolipid complexes in multifocal motor neuropathy.

BACKGROUND: Measurement of anti-GM1 IgM antibodies in multifocal motor neuropathy (MMN) sera is confounded by relatively low sensitivity that limits clinical usefulness. Combinatorial assay methods, in which antibodies react to heteromeric complexes of two or more glycolipids, are being increasingl...

Full description

Bibliographic Details
Main Authors: Galban-Horcajo, F, Fitzpatrick, A, Hutton, A, Dunn, S, Kalna, G, Brennan, K, Rinaldi, S, Yu, R, Goodyear, C, Willison, H
Format: Journal article
Language:English
Published: 2013
_version_ 1826296308480081920
author Galban-Horcajo, F
Fitzpatrick, A
Hutton, A
Dunn, S
Kalna, G
Brennan, K
Rinaldi, S
Yu, R
Goodyear, C
Willison, H
author_facet Galban-Horcajo, F
Fitzpatrick, A
Hutton, A
Dunn, S
Kalna, G
Brennan, K
Rinaldi, S
Yu, R
Goodyear, C
Willison, H
author_sort Galban-Horcajo, F
collection OXFORD
description BACKGROUND: Measurement of anti-GM1 IgM antibodies in multifocal motor neuropathy (MMN) sera is confounded by relatively low sensitivity that limits clinical usefulness. Combinatorial assay methods, in which antibodies react to heteromeric complexes of two or more glycolipids, are being increasingly applied to this area of diagnostic testing. METHODS: A newly developed combinatorial glycoarray able to identify antibodies to 45 different heteromeric glycolipid complexes and their 10 individual glycolipid components was applied to a randomly selected population of 33 MMN cases and 57 normal or disease controls. Comparison with an enzyme-linked immunosorbent assay (ELISA) was conducted for selected single glycolipids and their complexes. RESULTS: By ELISA, 22/33 MMN cases had detectable anti-GM1 IgM antibodies, whereas 19/33 MMN samples were positive for anti-GM1 antibodies by glycoarray. Analysis of variance (anova) revealed that of the 55 possible single glycolipids and their 1:1 complexes, antibodies to the GM1:galactocerebroside (GM1:GalC) complex were most significantly associated with MMN, returning 33/33 MMN samples as positive by glycoarray and 29/33 positive by ELISA. Regression analysis revealed a high correlation in absolute values between ELISA and glycoarray. Receiver operator characteristic analysis revealed insignificantly different diagnostic performance between the two methods. However, the glycoarray appeared to offer slightly improved sensitivity by identifying antibodies in four ELISA-negative samples. CONCLUSIONS: The use of combinatorial glycoarray or ELISA increased the diagnostic sensitivity of anti-glycolipid antibody testing in this cohort of MMN cases, without significantly affecting specificity, and may be a useful assay modification for routine clinical screening.
first_indexed 2024-03-07T04:14:20Z
format Journal article
id oxford-uuid:c8e80a1e-241f-420e-8449-eaec0e583fbe
institution University of Oxford
language English
last_indexed 2024-03-07T04:14:20Z
publishDate 2013
record_format dspace
spelling oxford-uuid:c8e80a1e-241f-420e-8449-eaec0e583fbe2022-03-27T06:55:19ZAntibodies to heteromeric glycolipid complexes in multifocal motor neuropathy.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:c8e80a1e-241f-420e-8449-eaec0e583fbeEnglishSymplectic Elements at Oxford2013Galban-Horcajo, FFitzpatrick, AHutton, ADunn, SKalna, GBrennan, KRinaldi, SYu, RGoodyear, CWillison, H BACKGROUND: Measurement of anti-GM1 IgM antibodies in multifocal motor neuropathy (MMN) sera is confounded by relatively low sensitivity that limits clinical usefulness. Combinatorial assay methods, in which antibodies react to heteromeric complexes of two or more glycolipids, are being increasingly applied to this area of diagnostic testing. METHODS: A newly developed combinatorial glycoarray able to identify antibodies to 45 different heteromeric glycolipid complexes and their 10 individual glycolipid components was applied to a randomly selected population of 33 MMN cases and 57 normal or disease controls. Comparison with an enzyme-linked immunosorbent assay (ELISA) was conducted for selected single glycolipids and their complexes. RESULTS: By ELISA, 22/33 MMN cases had detectable anti-GM1 IgM antibodies, whereas 19/33 MMN samples were positive for anti-GM1 antibodies by glycoarray. Analysis of variance (anova) revealed that of the 55 possible single glycolipids and their 1:1 complexes, antibodies to the GM1:galactocerebroside (GM1:GalC) complex were most significantly associated with MMN, returning 33/33 MMN samples as positive by glycoarray and 29/33 positive by ELISA. Regression analysis revealed a high correlation in absolute values between ELISA and glycoarray. Receiver operator characteristic analysis revealed insignificantly different diagnostic performance between the two methods. However, the glycoarray appeared to offer slightly improved sensitivity by identifying antibodies in four ELISA-negative samples. CONCLUSIONS: The use of combinatorial glycoarray or ELISA increased the diagnostic sensitivity of anti-glycolipid antibody testing in this cohort of MMN cases, without significantly affecting specificity, and may be a useful assay modification for routine clinical screening.
spellingShingle Galban-Horcajo, F
Fitzpatrick, A
Hutton, A
Dunn, S
Kalna, G
Brennan, K
Rinaldi, S
Yu, R
Goodyear, C
Willison, H
Antibodies to heteromeric glycolipid complexes in multifocal motor neuropathy.
title Antibodies to heteromeric glycolipid complexes in multifocal motor neuropathy.
title_full Antibodies to heteromeric glycolipid complexes in multifocal motor neuropathy.
title_fullStr Antibodies to heteromeric glycolipid complexes in multifocal motor neuropathy.
title_full_unstemmed Antibodies to heteromeric glycolipid complexes in multifocal motor neuropathy.
title_short Antibodies to heteromeric glycolipid complexes in multifocal motor neuropathy.
title_sort antibodies to heteromeric glycolipid complexes in multifocal motor neuropathy
work_keys_str_mv AT galbanhorcajof antibodiestoheteromericglycolipidcomplexesinmultifocalmotorneuropathy
AT fitzpatricka antibodiestoheteromericglycolipidcomplexesinmultifocalmotorneuropathy
AT huttona antibodiestoheteromericglycolipidcomplexesinmultifocalmotorneuropathy
AT dunns antibodiestoheteromericglycolipidcomplexesinmultifocalmotorneuropathy
AT kalnag antibodiestoheteromericglycolipidcomplexesinmultifocalmotorneuropathy
AT brennank antibodiestoheteromericglycolipidcomplexesinmultifocalmotorneuropathy
AT rinaldis antibodiestoheteromericglycolipidcomplexesinmultifocalmotorneuropathy
AT yur antibodiestoheteromericglycolipidcomplexesinmultifocalmotorneuropathy
AT goodyearc antibodiestoheteromericglycolipidcomplexesinmultifocalmotorneuropathy
AT willisonh antibodiestoheteromericglycolipidcomplexesinmultifocalmotorneuropathy